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AbstrAct
Background: Phase I trial was conducted to determine feasibility and toxicity of 
helical intensity-modulated radiotherapy (IMRT)-based stereotactic body radiotherapy 
(SBRT) for hepatocellular carcinoma (HCC).
Results: Eighteen patients (22 lesions) were enrolled. With no DLT at 52 Gy (13 Gy 
/fraction), protocol was amended for further escalation to 60 Gy (15 Gy/fraction). 
Radiologic complete response rate was 88.9%. Two outfield intrahepatic, 2 distant,  
4 concurrent local and outfield, and 1 concurrent local, outfield and distant failures (no 
local failure at dose levels 3–4) occurred. The worst toxicity was grade 3 hematologic 
in five patients, with no gastrointestinal toxicity > grade 1. At median follow-up 
of 28 months for living patients, 2-year local control, progression-free (PFS), and 
overall survival rates were 71.3%, 49.4% and 69.3%, respectively. Multi-segmental 
recurrences prior to SBRT was independent prognostic factor for PFS (p = 0.033). 
Materials and Methods: Eligible patients had Child-Pugh’s class A or B, 
unresectable HCC, ≤ 3 lesions, and cumulative tumor diameter ≤ 6 cm. Starting at 
36 Gy in four fractions, dose was escalated with 2 Gy/fraction per dose-level. CTCAE 
v 3.0 ≥ grade 3 gastrointestinal toxicity and radiation induced liver disease defined 
dose-limiting toxicity (DLT).
Conclusions: Helical IMRT-based SBRT was tolerable and showed encouraging 
results. Confirmatory phase II trial is underway.
INtrODUctION
The most common etiology for hepatocellular 
carcinoma (HCC) in Korea is viral infection (hepatitis 
B and C), and a large proportion of newly diagnosed 
HCC accompany advanced cirrhosis [1]. Surgical 
resection and percutaneous ablation can provide long-
term overall survival [2]; however, eligibility for these 
curative procedures is limited by preexisting conditions 
including hepatic dysfunction, tumor number and size, 
and vascular invasion. Stereotactic body radiotherapy 
(SBRT) has shown high rates of local control for primary 
and metastatic liver cancers [3–5]. In SBRT, a biologically 
equivalent dose > 100 Gy is delivered using highly 
conformal, hypofractionated radiation in 2-5 fractions [6], 
and this technique requires precision targeting and 
reproducibility in treatment setting. Given the steep dose 
fall-off and reduced number of fractions, the risk of local 
failure and normal tissue injury due to geometric miss 
is high with SBRT. Thus, major challenges in achieving 
safe and accurate SBRT for intrahepatic tumors include 
defining and limiting respiratory liver motion during 
treatment and providing accurate daily image-guidance. 
Helical Tomotherapy (HT) (Accuray, Madison, 
WI) is well-suited for delivering SBRT. The use of up to 
51 beam angles for treatment planning allows for highly 
conformal dose distributions with improved sparing of 
normal tissues compared to more conventional 3D plans 
[7]. HT-based SBRT is often utilized for treating brain 
[8] or spine lesions [9]; however, its role in treating 
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intrahepatic tumors has not been explored. HT is effective 
in treating multiple targets simultaneously, and we have 
previously shown its adequacy for multiple metastatic 
tumors [10]. The ability of HT to target multiple lesions 
simultaneously has been demonstrated for intrahepatic 
tumors [11] as well, and this is an important ability for 
liver SBRT, because most studies allowed patients with up 
to three intrahepatic lesions for eligibility [12, 13].
Image guidance for HT is provided via CT detector 
mounted opposite the radiation source, which is used 
for megavoltage CT (MVCT) imaging [14]. A common 
problem in using MVCT for image guidance is the low 
contrast resolution observed with the MVCT imaging 
system relative to kilovoltage (kV) CT [15], particularly 
when localizing treatment sites in the abdomen. However, 
the contour of the entire liver can be a surrogate, and rigid 
liver-to-liver registration using MVCT in combination 
with respiration control can be an effective image-
guidance system for liver tumors.
We have been using HT with MVCT image 
guidance for treating locally advanced HCC at our 
institution since 2006 [16]. We report the results of a phase 
I dose escalation trial that was designed to determine the 
feasibility and toxicity of helical intensity-modulated 
radiotherapy (IMRT)-based SBRT for primary HCC.
rEsULts
Patients
From March 2012 to April 2014, 18 patients with 
22 lesions were enrolled. Table 1 shows the demographic 
and treatment data. All patients had Child-Turcotte-Pugh 
(CTP) A (score 5 in 17 patients and 6 in one patient), 
and no patient had portal vein tumor thrombosis. The 
median cumulative tumor diameter was 2.05 cm (range 
1.0–4.4 cm). The dose was initially escalated to 52 Gy 
(13 Gy/fraction) without DLT. The protocol was amended 
for a further escalation to 60 Gy (15 Gy/fraction). The 
total number of patients analyzed in this study included 
additional patients enrolled in dose levels 1 and 3 while 
the amended protocols were being approved. Table 2 
shows the dosimetric parameters from the radiotherapy 
planning. The median value for PTV was 79.9 cc (8.16 to 
225.3 cc). The median normal liver volume was 1124 cc 
(801 to 1736 cc), and the median value of the mean dose 
to normal liver was 9.7 Gy (3.0 to 14.3 Gy).
toxicity
SBRT was well tolerated, with no DLT observed at any 
level. Table 3 shows toxicities that worsened from pre-SBRT 
(baseline) conditions, within the first 3 months after SBRT 
or prior to salvage treatment in case of treatment failure. The 
worst liver toxicity was grade 2 hyperbilirubinemia in one 
patient, and no GI toxicity greater than grade 1 occurred. 
Grade 3 leukocytopenia and thrombocytopenia developed 
in two and five patients, respectively. Six of these patients 
had grade 2 and one had grade 1 hematologic events prior 
to SBRT. Grade 2 radiation pneumonitis occurred in one 
patient with HCC in segment 8.
response rate and tumor control
A radiologic CR was achieved in 16 patients 
(88.9%) with a median time to a radiologic CR of 
6.0 months (range 0.7-12.3 months). One patient at dose 
level 1 achieved a pathologic CR, which was confirmed at 
liver transplantation 14 months after SBRT. Nine patients 
experienced disease progression: 2 outfield intrahepatic, 
2 distant, 4 local and outfield, and 1 local, outfield and 
distant failures (Figure 1). At dose level 1, one outfield 
intrahepatic failure, 1 concurrent local and outfield, and 
1 outfield failure followed by local failure were observed. 
At dose level 2, one local failure followed by outfield 
failure and 1 lung metastasis were observed. At dose level 
3, one outfield failure and 1 lung metastasis were observed, 
and another patient experienced outfield failure followed 
by local failure which was due to tumor progression into 
the treated area. At dose level 4, one patient experienced 
concurrent outfield failure and lung metastasis followed 
by local failure which was due to rapid tumor progression 
into the treated area. 
survival and prognostic factors
At a median follow-up of 23 months (range 
11–38 months) for all patients and 28 months (range 
13–38 months) for living patients, the 1- and 2-year 
local control rates were 77.8% and 71.3%, outfield 
intrahepatic progression-free survival rates were 61.1% 
and 61.1%, distant metastasis-free survival rates were 
88.9% and 83.0%, progression-free survival (PFS) rates 
were 55.6% and 49.4%, and overall survival rates were 
94.4% and 69.3%, respectively (Figure 2A and 2B). 
Table 4 shows the results of univariate and multivariate 
analyses of the clinical factors influencing PFS. 
Multi-segmental recurrences prior to SBRT showed a 
significant correlation with poor PFS rates in univariate 
(p = 0.029) and multivariate analyses (p = 0.033). PFS 
and OS of the patients with (n = 10) and without multi-
segment recurrences (n = 8) are shown in Figure 2C 
and 2D. Seven of the 10 patients with multi-segmental 
recurrences showed failures after SBRT: 1 local, 4 out-
field intrahepatic, 1 lung metastasis, and 1 synchronous 
outfield intrahepatic and lung metastasis.
DIscUssION
Challenges in treating intrahepatic tumors with RT 
include defining and limiting respiratory liver motion, 
accurate delineation of hypovascular tumors, minimizing 
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table 1: Demographic and treatment data (n = 18)
characteristics No. of patients (%)
Sex Female : Male 4 : 14 (22.2 : 77.8)
Age Median 59.5 years (range 42–83)
Hepatitis etiology B 14 (77.8)
C 1 (5.5)
nonB/nonC 3 (16.7)
Previous treatments None 3 (16.7)
Multiple TACE 6 (33.3)
Multiple TACE+RFA 4 (22.2)
Multi-modality* 5 (27.8)
Hepatic segment with recurrence Single 8 (44.4)
Multiple 10 (55.6)
Child-Pugh Score A (5) 17 (94.4)
A (6) 1 (5.6)
AFP > 9 ng/ml at RT 11 (61.1)
PIVKA > 35 mIU/ml at RT 10 (55.6)
Portal vein thrombosis No 18 (100)
Number of lesions 1 15 (83.3)
2 2 (11.1)
3 1 (5.6)
Maximum tumor diameter Median 1.95 cm (range 1.0–3.3)
Cumulative tumor diameter Median 2.05 cm (range 1.0–4.4)
Dose per fraction/total dose 9 Gy/36 Gy 4 (22.2)
11 Gy/44 Gy 3 (16.7)
13 Gy/52 Gy 8 (44.4)
15 Gy/60 Gy† 3 (16.7)
*Resection + TACE + RFA (n = 2), resection + TACE + sorafenib (n = 1), TACE + hepatic arterial chemotherapy + RFA 
(n = 1), and TACE + sorafenib + hepatic arterial chemotherapy (n = 1).
†Dose level 4 (15 Gy × 4 fractions) was added after no DLT was observed at level 3.
Abbreviations: RFA = Radiofrequency ablation; TACE = Transarterial chemoembolization; AFP = Alpha-feto protein; 
PIVKA = Proteins induced by vitamin K absence or antagonist-II; UICC = International union against cancer.
intrafractional- and interfractional uncertainties, and 
poor resolution of tumor in x-ray images used for image 
guidance. A simple method to overcome these limitations 
is increasing the PTV margins; however, without effective 
management of liver motion, the volume of non-target 
liver will increase, hence increasing hepatic toxicity. 
Abdominal compression is a simple and effective method 
of reducing diaphragmatic motion. Using gold fiducial 
markers, Wunderlink et al. showed that abdominal 
compression was effective in reducing liver tumor motion, 
yielding small and reproducible excursions in three 
dimensions [17]. Using rigid liver-to-liver registration 
of cone beam CT (CBCT) to planning CT, Eccles et al. 
showed that interfraction liver deformations and GTV 
displacement in patients undergoing SBRT with abdominal 
compression were small in most patients [18].
Fiducial markers have the advantage of being 
visible on x-ray images and fluoroscopy loops, hence 
increasing targeting accuracy in image-guided SBRT for 
intrahepatic tumors. However, fiducial placement carries 
risks specific to markers including migration, additional 
costs, and imaging artifacts on CT. Procedure-related risks 
include pain, pneumothorax, hemothorax, perforation of 
non-target organs, infection, and tumor seeding. These 
risks can increase substantially with insertion of multiple 
markers [19]. An alternative is to use the contour of the 
entire liver as a surrogate. HT uses onboard MVCT for 
image guidance. Intrahepatic tumors are known to be 
poorly visible in MVCT as well as in CBCT images. Since 
installation of HT at our institution in 2006, we have been 
using rigid liver-to-liver registration of MVCT to planning 
CT for treatment with HT [20]. Slow acquisition of MVCT 
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may be a disadvantage; however, abdominal compression 
reducing breathing motion to < 5 mm and liver-to-liver 
registration in the 3-dimensional view improves accuracy 
of image-guidance [21]. Comparison of pre- and post-
treatment setup corrections in the current study has shown 
MVCT is an adequate tool for image-guidance in treating 
hepatic tumors (Table 5 and Figure 3). Another advantage 
of HT is its effectiveness in treating multiple targets 
simultaneously [11], and potential benefits include reduced 
time for treatment set-up and delivery and increased 
patient compliance.
Our results suggest that helical IMRT-based SBRT 
is an effective tool for local control of up to three HCCs 
targeted simultaneously, provided that an adequate dose 
table 2: Dosimetric parameters
PTV volume Median 79.9 cc (range 8.2–225.3)
Volume of normal liver Median 1124 cc (range 801–1736)
Mean dose to normal liver Median 9.7 Gy (range 3.0–14.3)
Dose to 700 cc normal liver Median 2.65 Gy (range 0.5–10)
Volume of normal liver receiving < 2.5 Gy Median 800 cc (range 208–1233)
< 5.0 Gy Median 582 cc (range 160–1074)
< 7.5 Gy Median 488 cc (range 131–915)
< 10.0 Gy Median 391 cc (range 101–700)
< 12.5 Gy Median 311 cc (range 89–533)
< 15.0 Gy Median 223 cc (range 65–402)
Max dose to bowel/stomach Median 14.3 Gy (range 0.1–26.4)
Max dose to spinal cord Median 11.0 Gy (range 4.8–19.5)
Abbreviations: PTV = Planning target volume.
Figure 1: Patterns of all failure.
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Liver function AST 7 0 0
ALT 4 0 0
Albumin 0 1 0
ALP 1 0 0
Bilirubin 0 1 0
INR 1 0 0
Hematologic Leukocytes 6 7* 2†
Hemoglobin 1 0 0
Platelets 2 1‡ 5§
Gastrointestinal Anorexia 3 0 0
Nausea 1 0 0
Other Fatigue 4 1 0
Pain 1 0 0
Pulmonary RT pneumonitis 6 1 0
Worsening toxicities due to SBRT are recorded; toxicities due to salvage treatment after treatment failure are not recorded.
*Four patients had grade 1 leukocytopenia prior to SBRT.
†Two patients had grade 2 leukocytopenia prior to SBRT.
‡One patient had grade 1 thrombocytopenia prior to SBRT.
§Four patients had grade 2 and one patient had grade 1 thrombocytopenia prior to SBRT.
Abbreviations: CTCAE = Common terminology criteria for adverse events; AST = Aspartate Aminotransferase; 
ALT = Alanine aminotransferase; ALP = Alkaline phosphatase; INR = International normalization ratio.
Figure 2: Survival curves showing local failure-free (LFFS), intrahepatic out-field progression-free (OutPFS), distant 
metastasis-free (DMFs), progression-free (PFs) and overall survival (Os) for all patients (4A and 4b). PFS and OS of the 
patients with (n = 10) and without multi-segment recurrences (n = 8) are shown in Figure 4C and 4D.
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Table 4: Factors influencing progression-free survival
Prognostic factors No of Pts (%)
Univariate analysis Multivariate analysis
2-yr PFs (%) 95% cI P rr 95% cI P
Dose level
 3–4 11 (61) 63.6 35–92 0.209 2.425 0.47–12.6 0.293
 1–2 7 (39) 28.6 0–62
Age
 < 60 9 (50) 44.4 12–77 0.580
 ≥ 60 9 (50) 53.3 19–87
Etiology
 Other 4 (22) 50.0 1–99 0.694
 HBV 14 (78) 49.0 22–76
Pre-RT AFP
 < 9 ng/ml 6 (33) 25.0 0–65 0.389
 ≥ 9 ng/ml 12 (67) 58.3 30–86
Cumul diameter
 < 3 cm 13 (72) 61.5 35–87 0.100 4.003 0.42–38.3 0.229
 ≥ 3 cm 5 (38) 20.0 0–55
Multiplicity
 No 15 (83) 52.5 27–788 0.289 0.698 0.06–8.7 0.780
 Yes 3 (17) 33.3 0–87
Multi-segments
 No 8 (44) 72.9 41–100 0.029 8.561 1.20–61.3 0.033
 Yes 10 (56) 30.0 2–58
Abbreviations: RR = Relative risk; HBV = Hepatitis B virus.
table 5: comparison of pre- and post-treatment setup corrections
Location of tumor Pre-sbrt displacement
r* (average ± sD, mm)
Post-sbrt displacement 
r* (average ± sD, mm)
Group I (segment 1), n = 1 3.9 ± 1.2 1.1 ± 0.7
Group II (segments 2–4), n = 3 6.3 ± 2.8 1.5 ± 1.0
Group III (segments 5–6), n = 1 7.5 ± 1.3 2.6 ± 0.8
Group IV (segments 7–8), n = 10 5.0 ± 2.0 1.6 ± 1.1
All groups, n = 14 5.4 ± 2.3 1.6 ± 1.1
*R X Y Z= + +2 2 2
of radiation is delivered. Another contributing factor for 
improving local control may be the added margin for 
microscopic satellite lesions. Clinicopathologic studies 
have shown that microscopic satellite lesions of HCC can 
be detected 5–10 mm around the gross tumor [22, 23]; 
thus, providing adequate margins is an important but often 
overlooked issue. Previous dose escalation studies defined 
CTV as GTV [12] or ITV [13] without an additional 
margin, whereas we added a 5 mm margin to ITV to 
define CTV in order to cover microscopic satellite lesions. 
Extra measures including the use of 4D CT and abdominal 
compression allowed safe incorporation of the additional 
margin without increasing PTV substantially.
DLT was not reached even after the dose was 
escalated to a higher level than initially planned. Our 
results suggest that a further dose escalation may be 
possible if eligibility criteria are strictly met. Local 
control of HCCs, which are relatively radiosensitive, 
seems achievable at dose level 3; however patients with 
intrahepatic cholangiocarcinoma and metastatic tumors 
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Figure 3: comparison of pre- and post-treatment setup corrections for 4 fractions. Patients are grouped according to tumor 
location (Group I: segment 1; Group II: segments 2, 3, and 4; Group III: segments 5 and 6; and Group IV: segments 7 and 8).
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such as those from colorectal cancer may require a 
higher dose for prolonged local control. These patients 
may benefit from further dose escalation, since the liver 
function is not compromised by long-term exposure of the 
liver to viral hepatitis or alcohol consumption.
Use of SBRT for HCC is often initiated only after 
multiple attempts for local control in curative as well 
as palliative settings [6]. Many studies have shown the 
efficacy of SBRT in local control for HCC. Although 
it seems obvious that patients with multi-segmental 
recurrences are prone to intrahepatic out-field failures, this 
is the first prospective study to show that these patients 
may not be good candidates for SBRT. We suggest that a 
history of multi-segmental recurrences may need to be an 
exclusion criterion if SBRT is to be used with a curative 
aim. Another approach may be to use SBRT in combination 
with transcatheter arterial chemoembolization (TACE). 
SBRT may be used for intrahepatic tumors after incomplete 
treatment with TACE [24], or in combination with TACE 
or sorafenib for the treatment of multiple HCCs.
The current study is limited by inclusion of mostly 
small tumors (range 1.0–3.3 cm), and the SBRT protocol 
needs to be verified for larger tumors. A phase II trial to 
determine the efficacy of the current SBRT protocol is 
underway. 
Helical IMRT-based SBRT was well-tolerated and 
showed promising results for adequately selected HCC 
patients. Exclusion of patients with multi-segmental 
recurrence prior to SBRT may improve out-field 
intrahepatic and extrahepatic failure rates.
MAtErIALs AND MEtHODs 
study end points and eligibility
The primary end point was toxicity assessment, and 
the secondary end point was local control rate. A diagnosis 
of HCC was based on either pathologic confirmation or 
radiologic findings with an elevated serum level of alpha-
fetoprotein (AFP) (> 400 ng/mL) in patients with a high 
risk of developing HCC [25].
Eligibility
The study protocol conforms to the ethical guidelines 
of the 1975 Declaration of Helsinki, and was approved 
by our Institutional Review Board (4-2011-0650). All 
subjects gave informed consent prior to enrollment. 
All enrolled cases were presented at a multidisciplinary 
tumor board at our institution. Inclusion criteria were as 
follows: primary HCC not suitable for surgery because 
it was technically or medically inoperable or because of 
the patient’s refusal; recurrence after multiple treatment 
including TACE and RFA; maximum tumor diameter 
≤ 5 cm for a single tumor or the sum of diameters being 
≤ 6 cm for up to 3 lesions; normal liver volume greater 
than 800 cm3; tumor located at least 1 cm from the wall of 
the stomach and/or bowel; no prior radiation therapy to the 
targeted area; adequate liver function (total bilirubin levels 
< 3 mg/dL, albumin levels > 2.5 g/dl, normal prothrombin 
time (PT) / partial thromboplastin time (PTT), and serum 
levels of aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) less than 3 times the upper limit 
of normal); adequate renal function (creatinine levels 
< 1.8 mg/dL or creatinine clearance > 50 mL/min); 
adequate hematological function (absolute neutrophil 
count, ANC ≥ 1500/mm3, platelet counts ≥ 50,000/
mm3, hemoglobin level > 9 g/dL), no chemotherapy 
within 14 days of SBRT; Eastern Cooperative Oncology 
performance status 0–2; Child-Turcotte-Pugh’s Class A or 
B; and age 20 years or older. 
Helical IMrt-based sbrt protocol
Patients were immobilized using Vac-LockTM 
(CIVCO, Coralville, Iowa) and an abdominal compression 
device was used to minimize internal organ motion. CT 
images were acquired over ten respiratory phases, with 
1.5 mm slice thicknesses, under shallow respiration using 
a 4-dimensional CT simulator (SOMATOM Sensation, 
Siemens, Munich, Germany). Simulation CT images were 
fused with images from dynamic CT and MRI in order to 
aid accurate target delineation. The gross tumor volume 
(GTV) included all detectable tumors, as determined by 
dynamic CT and MRI. Internal target volume (ITV) was 
obtained by summing the GTVs of all respiratory motion 
phases. In order to incorporate microscopic satellite 
lesions into the target volume, CTV was defined as ITV 
plus a 5 mm margin in all directions. A radial margin of 
5 mm and a craniocaudal margin of 7 mm were added 
to the CTV in order to define the planning target volume 
(PTV) (Figure 4). Helical IMRT-based SBRT planning 
was performed using a Hi-Art TomoTherapy Planning 
System (Accuray Inc., Madison, WI). The primary IMRT 
objectives were to maximize the dose to 95% of the 
PTV. Dose constraints included: at least 700 cc of total 
uninvolved liver receiving less than 15 Gy, less than or 
equal to 2/3 of the right kidney receiving greater than 
15 Gy, maximum spinal cord dose 18 Gy, and maximum 
dose to the stomach or bowel 24 Gy. All patients were 
treated every-other-day with on-board MVCT for image-
guidance [20]. The entire liver was scanned with MVCT 
immediately before each fraction of SBRT. The MVCT 
was aligned with the planning kVCT, with special 
attention to ensure that tumor-containing hepatic segments 
were exactly matched. Three dimensional offsets, left-right 
(x-axis), craniocaudal (y-axis), and antero-posterior 
(z-axis) offsets were recorded.
Use of MVct for setup corrections
Two sets of MVCT scans, immediately before 
and after SBRT, were acquired for 14 patients (patients 
5 to 18). Three dimensional offsets in the left-right 
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(x-axis), craniocaudal (y-axis), and antero-posterior 
(z-axis) directions were recorded. Total displacement (R) 
was calculated using the equation:
R = + +X Y Z2 2 2  [9]
Hepatic segments were divided into 5 groups: 
segment 1 in Group I (n = 1), segments 2, 3, and 4 in 
Group II (n = 3), segments 5 and 6 in Group III (n = 1), 
and segments 7 and 8 in Group IV (n = 9) [20]. The mean 
pre- and post-SBRT total displacement (R) was 3.9 ± 1.2 
mm and 1.1 ± 0.7 mm for Group I, 6.3 ± 2.8 mm and 
1.5 ± 1.0 mm for Group II, 7.5 ± 1.3 mm and 2.6 ± 0.8 mm 
for Group III, 5.0 ± 2.0 mm and 1.6 ± 1.1 mm for Group 
IV, and 5.4 ± 2.3 mm and 1.6 ± 1.1 mm for all patients 
(Table 5). The MVCT offsets of pre- and post-SBRT are 
shown in Figure 3.
Dose escalation
Dose escalation started at 36 Gy (9 Gy/fraction) 
delivered in four fractions for PTV with a subsequent 
planned escalation of 2 Gy/fraction per dose-level. Three 
patients had to be treated in each dose level with no 
dose limiting toxicity within 1 month after SBRT before 
escalation to the next level was permitted. If toxicity 
occurred, a minimum of six patients were treated at that 
level.
Evaluation
Patients were assessed during SBRT and after 
completion of treatment at 1 month, every 3 months for the 
first 12 months, and every 6 months thereafter. Dynamic 
liver CT or MRI was performed at each follow-up. 
Toxicity was graded using the CTCAE version 3.0. 
Dose-limiting toxicity (DLT) was defined as grade 3 or 
greater hepatic, GI toxicity occurring within 1 month 
of SBRT, or radiation induced liver disease (RILD) 
requiring treatment in the absence of disease progression 
within 3 months of SBRT [26]. The Modified Response 
Criteria In Solid Tumors (mRECIST) was used to evaluate 
treatment response [27]. Local failure was defined as an 
in-field recurrence within the high-dose region (> 80% 
isodose volume), or mRECIST progressive disease. Out-
field recurrence was categorized into intrahepatic and 
extrahepatic (distant metastasis) recurrences.
statistical analysis
Local failure-free (LFFS), outfield intrahepatic 
failure-free (OFFFS), distant metastasis-free (DMFS), 
progression-free (PFS), and overall survival (OS) were 
estimated using the Kaplan-Meier method. Survival rates 
were defined as the time between the last day of SBRT 
and the first event. Events were death from any cause for 
Figure 4: target volumes and dose distribution for helical IMrt based-sbrt. ITV is shown as a solid red line and PTV as 
a solid blue line for two target lesions.
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OS, death or tumor progression for PFS, and recurrences 
as defined above for LFFS, OFFFS, and DMFS. Cox 
regression analysis was used for multivariate analysis. 
P values less than 0.05 were considered significant.
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